Bone Marrow Transplant for Myelofibrosis

What is a Bone Marrow Transplant?

For allogeneic hematopoietic cell transplantation (otherwise known as a bone marrow or stem cell transplant), hematopoietic (blood-forming) stem cells are transferred from a donor to the patient, essentially replacing defective stem cells with healthy ones. Before the stem cell infusion, the patient receives high doses of chemotherapy and/or radiation therapy to eradicate diseased bone marrow.

Allogeneic hematopoietic cell is currently the only treatment approach in MF that is potentially curative, with a substantial number of patients experiencing complete hematological, histological and molecular remission. However, such therapy is complicated by relatively high treatment-related mortality and morbidity. 

Who is a candidate?

Of the MPNs, only those diagnosed with myelofibrosis would be considered for a transplant. Within that population, only a subset of people will be healthy enough to undergo a transplant. Patients need to carefully discuss whether or not they may be eligible for such a procedure, given the complexity and possibility for complications. Since age and the presence of other diseases elevates the risks associated with ASCT, the decision to pursue ASCT should take into consideration the patient’s risk tolerance and transplant-related prognostic score (a rough measure of likely success, based on factors specific to the patient and the transplant).

Paying for Transplant

As of 2016, Medicare now provides coverage for stem cell transplant for those patients who need one. The coverage is reserved for myelofibrosis patients who have a Dynamic Prognostic Scoring System ingermediate-2 or High primary or secondary MF score. They must also agree to participate in a prospective clinical study to evaluate their outcomes vs patients with the same score who are not undergoing a Stem Cell Transplant. 

Read Stories of Others Who have Undergone Transplant:


Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia. H. Joachim Deeg et al. Biology of Blood and Marrow Transplantation,  March 2007Volume 13, Issue 3, Pages 355–365

Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. A. Tefferi. Bone Marrow Transplantation (2010) 45, 419–421; doi:10.1038/bmt.2009.193

Take the steps you need to help change your prognosis.



Get free, timely information on living with an MPN.